Biotechnology company Nuclera has partnered with leadXpro on structure-based drug design for complex membrane proteins. 

The collaboration will bring together Nuclera’s eProtein Discovery system with leadXpro’s AI/ML-driven construct design and membrane protein expertise to advance structural studies and therapeutic development. 

Membrane proteins remain some of the most valuable yet difficult to obtain drug targets. The proteins are notoriously challenging to express and purify in sufficient quantity and quality for structural biology and biophysical studies, limiting drug discovery programmes even when promising biology is well understood. 

As part of the collaboration, membrane protein constructs will be screened using Nuclera’s eProtein Discovery System with the most promising variants undergoing detailed biophysical characterisation and high-resolution cryo-EM structure determination, led by leadXpro. Insights from these studies will be integrated into AI/ML models for construct design and stability predictions, which the companies hope will improve yields, functionality, and success rates.  

“Scientists are under pressure to progress increasingly complex membrane protein programmes faster,” said Dr Michael Chen, CEO and Co-Founder of Nuclera. 

“By partnering with leadXpro, we can pair AI/ML-driven construct design with our rapid multiplex membrane protein screening to provide a truly ‘lab-in-loop’ workflow. This collaboration is an important step towards embedding AI/ML into Nuclera’s system so that researchers can go from sequence to high-value structural and functional insights in a fraction of the time currently required.” 

“Access to well-optimised membrane protein constructs is critical for producing high-quality proteins that enable biophysical and structural biology studies,” added Dr Michael Hennig, CEO of leadXpro. 

“Nuclera’s eProtein Discovery platform provides a robust, rapid, and reproducible approach to exploring construct space. Combined with our established AI/ML and structural biology expertise, this integration allows us to support better design decisions earlier and accelerate the progression of promising drug candidates.”